J. Serna

发表

Characterization and prognostic implication of 17 chromosome abnormalites in myelodysplastic syndrome Running title : Chromosome 17 abnormalities in MDS

Adriana, F. Solé, J. Cervera, 2022 .

Leucoencefalopatía multifocal progresiva en un paciente con leucemia mieloide aguda sometido a trasplante alogénico de progenitores hematopoyéticos

M. Fernández-Ruiz, F. López-Medrano, J. Serna, 2011 .

Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients

J. San-Miguel, J. Bladé, J. Lahuerta, 2000, British journal of haematology.

Long-term results of fludarabine/melphalan as a reduced-intensity conditioning regimen in mantle cell lymphoma: the GELTAMO experience

R. Martino, J. Díez-Martín, P. Balsalobre, 2011, Therapeutic advances in hematology.

Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study

U. Jaeger, T. Kipps, A. Kater, 2017 .

Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial

H. Döhner, M. Hallek, S. Stilgenbauer, 2013 .

Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma

J. Miguel, J. Bladé, J. Lahuerta, 2000, British journal of haematology.

Allogeneic transplantation of CD34+-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation

E. Montserrat, J. Garcia-conde, C. Solano, 2001, Bone Marrow Transplantation.

Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in the Elderly: A Joint Analysis of the French -Belgian-Swiss and PETHEMA Groups.

H. Dombret, E. Vellenga, S. Chevret, 2009 .

Late Relapses in APL Treated with ATRA and Anthracycline Based Chemotherapy: The European APL Group Experience (APL 91 and APL 93 Trials).

H. Dombret, A. Vekhoff, S. Chevret, 2005 .

Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry

C. Solano, S. Brunet, F. Hernández-Navarro, 1998, Bone Marrow Transplantation.

Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant

R. Martino, J. Miguel, Á. Urbano-Ispizua, 2002, Bone Marrow Transplantation.

ADMINISTRATION OF rHuG–CSF TO YOUNG DONORS

A. Verdeguer, M. Sanz, S. Brunet, 2002 .

Comparison Between Lymphoglobuline- and Thymoglobuline-Based Immunosuppressive Therapy as First-Line Treatment for Patients with Aplastic Anemia.

E. Colado, A. Rosell, S. Brunet, 2009 .

Iron depletion by phlebotomy with recombinant erythropoietin prior to allogeneic transplantation to prevent liver toxicity

R. Bornstein, M. García-Bueno, J. Serna, 1999, Bone Marrow Transplantation.

Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia

J. Miguel, H. Dombret, C. Chastang, 1998 .

Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS

J. Sanz, J. Lahuerta, G. Sanz, 2016, Bone Marrow Transplantation.

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy

J. Esteve, L. Escoda, E. Vellenga, 2018, Leukemia.

Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry

C. Solano, A. Verdeguer, S. Brunet, 1999, Bone Marrow Transplantation.

Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

U. Jaeger, T. Kipps, A. Kater, 2020 .

Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience

J. Miguel, J. Bourhis, H. Dombret, 2005, Leukemia.

Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

A. Zelenetz, J. Delgado, S. Stilgenbauer, 2016 .

Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients

A. Oriol, J. Rodríguez, J. Lahuerta, 2011, International journal of hematology.

All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies

A. Ganser, F. Lo‐Coco, E. Vellenga, 2015, Annals of Hematology.

Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial

J. Miguel, H. Dombret, A. Vekhoff, 2003, Leukemia.

The use of an expanded circulating hematopoietic progenitor cell pool associated with bone marrow fibrosis for the support of autologous transplantation in IgD multiple myeloma

R. Bornstein, J. Serna, J. Lahuerta-Palacios, 1997, Bone Marrow Transplantation.

Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple Myeloma

J. Miguel, C. Solano, J. Bargay, 2002, Leukemia & lymphoma.

Induction with Fludarabine, Cyclophosphamide and Rituximab Followed by Maintenance with Rituximab: Results of a Prospective Study in 75 Patients (LNHF-03).

J. Martínez-López, C. Montalbán, M. Canales, 2006 .

Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom.

H. Dombret, M. Tallman, A. Falanga, 2005, Leukemia research.

Prognostic Factors in APL

M. Sanz, P. Montesinos, J. Serna, 2018 .

Allogeneic Transplant in Patients with Poor Prognosis B-Chronic Lymphocytic Leukemia (B-CLL): Comparative Study between Myeloablative(M) and Non-Myeloablative(NM) Conditioning Regimen.

J. Esteve, R. Martino, J. Díez, 2004 .

Incidence and Risk Factors for Thrombosis in Patients with Acute Promyelocytic Leukemia. Experience of the PETHEMA LPA96 and LPA99 Protocols.

J. Esteve, Marcos González, E. Vellenga, 2006 .

Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL

H. Dombret, A. Vekhoff, S. Chevret, 2008 .

Research Report Second Mobilization and Collection of Peripheral Blood Progenitor Cells in Healthy Donors Is Associated with Lower CD34 1 Cell Yields

A. Verdeguer, M. Sanz, S. Brunet, 2002 .

Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy.

A. Baruchel, G. Leverger, S. Chevret, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.

J. Esteve, D. Colomer, Marcos González, 2008, Blood.

Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.

A. López-Guillermo, J. Garcia-conde, J. Rifón, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.

J. Bourhis, H. Dombret, S. Chevret, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison between French -Belgian-Swiss and Spanish Results.

H. Dombret, A. Vekhoff, E. Vellenga, 2005 .

Title: Reproducible diagnosis of Chronic Lymphocytic Leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project

Stephen, E. Montserrat, N. Villamor, 2017 .

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study

Á. Illés, M. Šimkovič, P. Ghia, 2019, Hematological Oncology.

Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.

J. Miguel, H. Dombret, C. Chastang, 1998, Blood.

MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)

U. Jaeger, A. Kater, M. Lefebure, 2023, Hematological Oncology.

Substrate Reduction Therapy With Miglustat In Type 1 Gaucher Disease In Spain. Nine Years Outcomes Update On ZAGAL Study

L. Villalón, A. Bárez, E. Luño, 2013 .